Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). [electronic resource]
Producer: 20110411Description: 579-86 p. digitalISSN:- 1432-0843
- Administration, Oral
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Area Under Curve
- Carcinoma, Squamous Cell -- drug therapy
- Chromatography, Liquid
- Docetaxel
- Dose-Response Relationship, Drug
- Enzyme Induction -- drug effects
- Erlotinib Hydrochloride
- Female
- Head and Neck Neoplasms -- drug therapy
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Quinazolines -- administration & dosage
- Tandem Mass Spectrometry
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.